Spyre's SPY003 hits its Phase 2 goal in ulcerative colitis, completing its three-drug bowel-disease bet

Spyre TherapeuticsDealroom has a profile for this one. Try Dealroom → reported positive results from the first part of its Phase 2 SKYLINE trial of SPY003 in ulcerative colitis (UC), an inflammatory bowel disease that causes chronic ulcers and bleeding in the large intestine.